A real-world study found tildrakizumab improved skin clearance, symptoms, and quality of life in adults with plaque psoriasis ...

In this video from the American Academy of Dermatology Annual Meeting, April W. Armstrong, MD, MPH, discusses data presented ...

A recent study published in the journal of Dermatology and Therapy found Tildrakizumab to significantly improve disease ...

Please provide your email address to receive an email when new articles are posted on . There is an unmet need for a safe and effective oral treatment for moderate to severe plaque psoriasis. In two ...

Can you diagnosis this Derm Clinic? Patient presents with skin lesions on extremities, upper back, and chest. A 72-year-old man with insulin-dependent type 2 diabetes presents with a 6-month history ...

Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof ...

—A growing body of evidence has revealed several comorbidities associated with generalized plaque psoriasis. A new study takes a closer look at possible shared risks for a subtype, palmoplantar ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in ...

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

- NDA Is Supported by Positive Data From the Phase 3 PSOARING 1 and PSOARING 2 Pivotal Efficacy Trials and Interim Results From the PSOARING 3 Long-Term Safety Study - LONG BEACH, Calif. & BASEL, ...

Acne keloidalis nuchae (AKN) begins as papules and pustules that develop into firm crusted plaques. 1 Despite its name, AKN is not a keloid. 2 The posterior scalp and neck are the primary sites of ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to include ...